Publications by authors named "Allison Hollis"
A 23-year-old man with a viral-like prodrome developed sudden severe dyspnea and was found to have renal failure, anemia, shock, and diffuse alveolar hemorrhage with acute respiratory distress syndrome, requiring emergent endotracheal intubation and extracorporeal membrane oxygenation (ECMO). Travel and exposure history from peripheral sources revealed that the patient had participated in a 'mud-run' in Hawaii two weeks prior to symptom onset. The patient was subsequently diagnosed with leptospirosis and treated with ceftriaxone and doxycycline.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to analyze how common blood stream infections (BSIs) are in adult patients on extracorporeal membrane oxygenation (ECMO) in a single medical center that follows specific antibiotic practices post-cannulation.
- The retrospective study over five years found that 13.1% of VV ECMO patients and 5.7% of VA ECMO patients developed BSIs, with an incidence rate of 8 BSIs per 1,000 ECMO days for both types.
- The findings suggest that BSIs are prevalent despite antibiotic use, especially linked to longer ECMO duration, blood transfusions, and organ failures, indicating a need for more research on optimal antibiotic strategies during ECMO treatment.*
Prostacyclin (prostaglandin I [PGI]) is an eicosanoid lipid mediator produced by the endothelial cells. It plays pivotal roles in vascular homeostasis by virtue of its potent vasodilatory and antithrombotic effects. Stable pharmacological analogues of PGI are used for treatment of pulmonary hypertension and right ventricular failure.
View Article and Find Full Text PDFBackground: Cardiac transplantation can be complicated by refractory hemorrhage particularly in cases where explantation of a ventricular assist device is necessary. Recombinant activated factor VII (rFVIIa) has been used to treat refractory bleeding in cardiac surgery patients, but little information is available on its efficacy or cost in heart transplant patients.
Methods: Patients who had orthotopic heart transplantation between January 2009 and December 2014 at a single center were reviewed.
Background: A prospective, single center, open-label study was conducted to determine if the standard practice for surgical prophylaxis, which includes standardized dosing of cefazolin, at the University of Maryland Medical Center (UMMC) is adequate for patients placed on bypass during cardiac surgery.
Methods: All patients were given the same standard dosing regimen regardless of weight: two grams of cefazolin administered within 1 h of incision, an additional one gram injected into the bypass circuit at the onset of bypass, and two grams every 3 h after the initial dose. Cefazolin serum concentrations were collected immediately after incision, after the start of bypass, each hour of bypass, at the end of bypass and at sternal closure.